^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA mutation + PTEN mutation + KRAS mutation

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, PTEN, Phosphatase and tensin homolog, Mutated In Multiple Advanced Cancers 1, Phosphatase And Tensin Homolog, Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN, MMAC1, TEP1, MMAC1 Phosphatase And Tensin Homolog Deleted On Chromosome 10, Mitochondrial Phosphatase And Tensin Protein Alpha, Phosphatase And Tensin-Like Protein, Protein Tyrosine Phosphatase, Mitochondrial PTENalpha, PTENbeta, PTEN1, CWS1, GLM2, MHAM, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 5290; 5728
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over3years
    Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing. (PubMed, Am J Cancer Res)
    In contrast, somatic screening of BRCA mutations in BRCA-negative breast cancer patients has limited value. The results highlight the benefit of somatic testing to guide future research directions on other targeted therapies for breast and ovarian malignancies.
    Clinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • BRCA (Breast cancer early onset)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • PTEN mutation • BRCA mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] Study of Potential Mutations in the Genetic Profiles of Rectal Cancer Patients Before and After Neoadjuvant Chemoradiation (CAP 2020)
    Our results show reduction in variant heterogeneity with treatment in both groups that was not statistically significant. We identified multiple genetic variations in tumor DNA from rectal cancer patients who are poor responders to neoadjuvant chemoradiation, compared to complete responders. Further investigation is warranted.
    Clinical • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ABL1 (ABL proto-oncogene 1) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • FGFR3 (Fibroblast growth factor receptor 3) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • GNAQ (G Protein Subunit Alpha Q) • KMT2D (Lysine Methyltransferase 2D) • MSH6 (MutS homolog 6) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • PMS2 (PMS1 protein homolog 2) • CREBBP (CREB binding protein) • JAK1 (Janus Kinase 1) • KDM6A (Lysine Demethylase 6A) • EP300 (E1A binding protein p300)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • ATM mutation • PTEN mutation • ARID1A mutation • FGFR3 mutation • PMS2 mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers. (PubMed, Cancers (Basel))
    Our data obtained from the experiments, applying pharmacological inhibitors and genetic approaches, shows that YB-1 is a key player in cell proliferation, clonogenic activity, and tumor growth of TNBC cells through the MAPK and PI3K pathways. Therefore, dual inhibition of these two pathways or single targeting of YB-1 may be an effective strategy to treat TNBC.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • YBX1 (Y-Box Binding Protein 1)
    |
    KRAS mutation • PIK3CA mutation • PIK3CA H1047R • KRAS G13D • KRAS G13 • PIK3CA mutation + PTEN mutation + KRAS mutation • PTEN loss
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] KRAS mutations in NSCLC patients who never smoke: definition of a new patient subgroup (DGHO 2020)
    Never-smoking NSCLC patients with KRAS mutations represent a subgroup with marked genetic and clinical differences to the well-known smoker-cohort. Further work in the light of new targeted therapy approaches in this patient group is warranted.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • DDR2 (Discoidin domain receptor 2)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • PIK3CA mutation • KRAS G12D • PTEN mutation • KRAS G12V • FGFR2 mutation • ALK mutation • KRAS G12 • KRAS G13 • EGFR mutation + KRAS mutation • KRAS Q61 • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] KRAS mutations in NSCLC patients who never smoke: definition of a new patient subgroup (DGHO 2020)
    Never-smoking NSCLC patients with KRAS mutations represent a subgroup with marked genetic and clinical differences to the well-known smoker-cohort. Further work in the light of new targeted therapy approaches in this patient group is warranted.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • DDR2 (Discoidin domain receptor 2)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • PIK3CA mutation • KRAS G12D • PTEN mutation • KRAS G12V • FGFR2 mutation • ALK mutation • KRAS G12 • KRAS G13 • EGFR mutation + KRAS mutation • KRAS Q61 • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] Targeted next-generation sequencing of circulating tumor DNA identifies mutations in ESR1 and TP53 as the main predictors of progression-free and overall survival in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer (DGHO 2020)
    Mutations in ESR1 and TP53 are the main predictors of progression free and overall survival in oestrogen receptor-positive, HER2-negative MBC patients.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • ER positive • HER-2 negative • PIK3CA mutation • PTEN mutation • ER mutation • HRAS mutation • PIK3CA mutation + ER positive • AR mutation • ER positive + HER-2 negative • PIK3CA mutation + HRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] KRAS mutations in NSCLC patients who never smoke: definition of a new patient subgroup (DGHO 2020)
    Never-smoking NSCLC patients with KRAS mutations represent a subgroup with marked genetic and clinical differences to the well-known smoker-cohort. Further work in the light of new targeted therapy approaches in this patient group is warranted.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • DDR2 (Discoidin domain receptor 2)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • PIK3CA mutation • KRAS G12D • PTEN mutation • KRAS G12V • FGFR2 mutation • ALK mutation • KRAS G12 • KRAS G13 • EGFR mutation + KRAS mutation • KRAS Q61 • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    [VIRTUAL] KRAS mutations in NSCLC patients who never smoke: definition of a new patient subgroup (DGHO 2020)
    Never-smoking NSCLC patients with KRAS mutations represent a subgroup with marked genetic and clinical differences to the well-known smoker-cohort. Further work in the light of new targeted therapy approaches in this patient group is warranted.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • DDR2 (Discoidin domain receptor 2)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • PIK3CA mutation • KRAS G12D • PTEN mutation • KRAS G12V • FGFR2 mutation • ALK mutation • KRAS G12 • KRAS G13 • EGFR mutation + KRAS mutation • KRAS Q61 • PIK3CA mutation + PTEN mutation + KRAS mutation
    over3years
    Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer. (PubMed, Cancer Genomics Proteomics)
    Concurrent resistance mutations in genes other than EGFR influenced the outcome of patients with NSCLC, while non-resistance mutations did not alter survival, compared to the absence of co-mutations. This evidence highlights the importance of a careful interpretation of molecular findings. The best treatment options for these patients should be studied in randomized controlled trials.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    KRAS mutation • EGFR mutation • PIK3CA mutation • PTEN mutation • EGFR mutation + KRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    |
    Tagrisso (osimertinib)
    almost4years
    KIT-dependent and -independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1/2 inhibition as salvage strategy. (PubMed, Mol Cancer Ther)
    Using CRISPR/Cas9 methods, we generated a panel of GIST cell lines harboring mutations in KIT, PTEN, KRAS, NF1, and TSC2 We utilized this panel to evaluate sapanisertib, a novel mTOR kinase inhibitor, as a salvage strategy...Our isogenic cell line panel closely approximates the genetic heterogeneity of resistance observed in heavily pretreated GIST patients. With the clinical development of novel, broad spectrum KIT inhibitors, emergence of non-KIT-related resistance may require combination treatments with inhibitors of KIT-downstream signaling such as mTOR or MEK.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    KRAS mutation • PIK3CA mutation • PTEN mutation • NF1 mutation • PDGFRA mutation • TSC1 mutation • TSC2 mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    |
    sapanisertib (CB-228)
    almost4years
    [VIRTUAL] Deep targeted and whole exome sequencing identifies driver mutations in the airway epithelium of individuals at high risk for lung cancer (AACR-II 2020)
    This field of cancerization effect may provide a tool for risk assessment for lung cancer. This research was funded by U01CA196405 to PPM.
    Clinical • Tumor Mutational Burden
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    TP53 mutation • EGFR mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation • NF1 mutation • KEAP1 mutation • MET mutation • KEAP1 mutation + KRAS mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    almost4years
    [VIRTUAL] Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (AACR-II 2020)
    The clonal and subclonal mutational landscapes of RAS WT pts were analyzed using a mCRC-focused custom ctDNA sequencing panel. Randomized pts (1:1) received mFOLFOX6 plus either panitumumab or bevacizumab. The validated ultra-deep plasma sequencing panel was concordant with tissue sequencing and detected tumor heterogeneity. The PARADIGM study will report the efficacy of anti-EGFR/VEGF therapies; post-treatment collection of ctDNA is ongoing. The relationship between therapeutic effects and clonal and subclonal mutational landscapes will be examined in the future.
    P3 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • DNMT3A (DNA methyltransferase 1) • VEGFA (Vascular endothelial growth factor A) • TET2 (Tet Methylcytosine Dioxygenase 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS A146 • KRAS Q61 • KRAS K117 • NRAS A146 • NRAS A59 • PIK3CA mutation + PTEN mutation + KRAS mutation
    |
    Avastin (bevacizumab) • Vectibix (panitumumab)
    almost4years
    [VIRTUAL] Targeted next generation sequencing identifies somatic variants in Egyptian breast cancer patients (AACR-II 2020)
    We also identified 5 variants with uncertain significance (4 in TP53 and 1 in CEBPA) and 4 variants with conflicting interpretations of pathogenicity (2 in TP53 and 1 in each of APC and JAK3). Moreover, 4 novel variants were identified in JAK2, MTOR, KIT and EPHB.In this cohort, we shed the light on the most frequently detected somatic mutations in Egyptian BC patients which allows for more knowledge about BC progression.
    Clinical • Next-generation sequencing
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • JAK2 (Janus kinase 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • JAK3 (Janus Kinase 3)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • PTEN mutation • AKT1 mutation • JAK3 mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    almost4years
    Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population. (PubMed, Diagn Pathol)
    In our high-recurrence risk PTC cohort, most patients had more than one driver gene aberration. Coexistence of BRAF V600E with TERT promoter mutations or with RAS mutations were significantly correlated with worse clinicopathological characteristics.
    Clinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • PIK3CA mutation • BRAF V600 • RET fusion • PTEN mutation • HRAS mutation • AKT1 mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    almost4years
    [VIRTUAL] Impact of p-mTOR expression on molecular-guided therapy strategies in therapy-refractory metastatic pancreatic ductal adenocarcinoma (ESMO-GI 2020)
    The recommended treatments included everolimus (n=3), pembrolizumab (n=3), palbociclib (n=2) and cetuximab, crizotinib, FLT3 inhibitor, nintedanib, tamoxifen, and the combination of lapatinib and trastuzumab, each in one patient. Legal entity responsible for the study The authors. Funding Has not received any funding.
    BRCA Biomarker • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • FLT3 (Fms-related tyrosine kinase 3) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • SMAD4 (SMAD family member 4) • RSPO2 (R-Spondin 2)
    |
    HER-2 positive • TP53 mutation • KRAS mutation • BRCA2 mutation • PIK3CA mutation • HER-2 expression • EGFR expression • PTEN mutation • ER expression • PIK3CA mutation + PTEN mutation + KRAS mutation
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • Xalkori (crizotinib) • Ibrance (palbociclib) • everolimus • lapatinib • nintedanib
    4years
    [VIRTUAL] Mutation profile of colon cancer in hispanic population of central California. (ASCO 2020)
    "The frequency of actionable mutations was similar in both Hispanic and non-Hispanic patients. Hispanics were noted to have lower PIK3CA and microsatellite instability. Metastatic disease and right sided colon cancer were seen at higher frequency in Hispanic population."
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • PIK3CA mutation • ATM mutation • PTEN mutation • MYC amplification • PIK3CA amplification • PIK3CA mutation + PTEN mutation + KRAS mutation
    |
    FoundationOne® CDx
    4years
    Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients. (PubMed, J Adv Res)
    Further analysis, by Ingenuity Variant Analysis software (IVA), showed that PI3K/AKT signaling is altered in greater than 50% of Egyptian BC patients which implicates PI3K/AKT signaling as a therapeutic target. In this cohort, we shed the light on the most frequently detected somatic mutations and the most altered pathway in Egyptian BC patients.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • JAK2 (Janus kinase 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • JAK3 (Janus Kinase 3)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • PTEN mutation • AKT1 mutation • JAK3 mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    4years
    [VIRTUAL] Clinical outcomes of MSI-high (MSI-H) versus stable (MSS) endometrial carcinoma (EC) after front-line platinum chemotherapy and subsequent matched therapy. (ASCO 2020)
    "The 6 mth progression free survival (PFS) rate for MSS versus MSI-H pts treated with front-line carboplatin+paclitaxel (CP) was 83% versus 50% (RR 1.67, fisher’s exact 2-sided p=0.09), with a shorter median PFS after 1st line CP for MSI-H versus MSS pts (median 5.2 mth vs. 8.3 mth, not sig). MSI-H EC pts appear to have shorter PFS to front-line CP chemotherapy compared with MSS pts, but may derive durable responses from immunotherapy in subsequent-line therapy. Early use of immunotherapy in advanced MSI-H EC pts should be considered. Further optimisation of therapy is urgently needed in advanced MSS EC."
    Clinical data • Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    TP53 mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation • PIK3CA mutation + PTEN mutation + KRAS mutation
    |
    FoundationOne® CDx
    |
    carboplatin • paclitaxel